0 176

Cited 0 times in

Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.date.accessioned2021-12-28T16:44:20Z-
dc.date.available2021-12-28T16:44:20Z-
dc.date.issued2021-10-
dc.identifier.issn1936-0533-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186779-
dc.description.abstractBackground and aims: Whether entecavir (ETV) or tenofovir alafenamide (TAF) is better at preventing hepatocellular carcinoma (HCC) development among patients with chronic hepatitis B (CHB) remains unclear. The present study was conducted to explore the ability of these two antivirals to prevent HCC. Methods: From 2012 to 2019, treatment-naïve CHB patients undergoing ETV or TAF therapy were recruited at three academic teaching hospitals. The TAF group comprised patients starting TAF as first-line antiviral and those switching antivirals from tenofovir disoproxil fumarate to TAF. Patients with decompensated cirrhosis or HCC at enrollment were excluded from the analysis. Cumulative probabilities of HCC were assessed using the Kaplan-Meier method. Results: In total, 1810 patients (1525 and 285 in ETV and TAF groups, respectively) were recruited. The annual HCC incidence was statistically not different between the ETV and TAF groups (1.67 vs. 1.19 per 100 person-years, respectively) with an adjusted hazard ratio (HR) of 0.681 (p = 0.255), as determined by multivariate analysis. Male, hypertension, liver cirrhosis, FIB-4 index, and albumin were independent prognostic factors for HCC development. Propensity score-matched and inverse probability of treatment weighting analyses yielded similar results, with non-statistically different HCC incidence between the ETV and TAF groups (1.07 vs. 1.19 per 100 person-years (HR = 0.973; p = 0.953) and 1.67 vs. 1.89 per 100 person-years, respectively (HR = 0.949; p = 0.743). Conclusions: These findings suggest that ETV- and TAF-treated CHB patients have similar risk of developing HCC. Further studies with the larger sample size and longer follow-up are needed to validate these results.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfHEPATOLOGY INTERNATIONAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAlanine-
dc.subject.MESHAntiviral Agents / therapeutic use-
dc.subject.MESHCarcinoma, Hepatocellular* / drug therapy-
dc.subject.MESHCarcinoma, Hepatocellular* / epidemiology-
dc.subject.MESHCarcinoma, Hepatocellular* / prevention & control-
dc.subject.MESHGuanine / analogs & derivatives-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / drug therapy-
dc.subject.MESHLiver Neoplasms* / epidemiology-
dc.subject.MESHMale-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTenofovir / analogs & derivatives-
dc.subject.MESHTreatment Outcome-
dc.titleImpact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorYoung Youn Cho-
dc.contributor.googleauthorHyein Lee-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSoo Young Park-
dc.identifier.doi10.1007/s12072-021-10234-2-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ00986-
dc.identifier.eissn1936-0541-
dc.identifier.pmid34402025-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12072-021-10234-2-
dc.subject.keywordChronic hepatitis B-
dc.subject.keywordEntecavir-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordRisk factor-
dc.subject.keywordTenofovir alafenamide-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume15-
dc.citation.number5-
dc.citation.startPage1083-
dc.citation.endPage1092-
dc.identifier.bibliographicCitationHEPATOLOGY INTERNATIONAL, Vol.15(5) : 1083-1092, 2021-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.